LAKEWOOD, Colo. – October 5, 2023 – Terumo Blood and Cell Technologies today announced the launch of a study with BioCentriq® to generate publicly available CAR-T cell manufacturing data using Terumo BCT's cell and gene therapy manufacturing platforms.
The study aims to generate open, accessible data on CAR-T cell manufacturing processes using Terumo BCT's automated platforms, helping to advance industry-wide understanding of process optimization for cell therapy manufacturing.
"By generating and sharing this data publicly, we hope to accelerate innovation across the cell and gene therapy industry," said a Terumo Blood and Cell Technologies representative. "This collaboration with BioCentriq reflects our commitment to advancing the field through open, collaborative research."
The resulting data set is intended to serve as a resource for researchers and manufacturers working to optimize CAR-T cell therapy production processes.
